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he incidence of pneumothorax resulting from bronchoal-
veolar fistula complicating primary or secondary lung
cancer ranges between 1% and 4%.1 Because of the rarity
of this condition (4 cases out of 663 admissions for lung
cancer [0.4%] during a 2-year period in our institution), preventing
the accumulation of large numbered series, and the anecdotal nature
of the reported cases, it has not been possible to investigate the path-
ophysiology and codify the possible therapeutic pathways indicated
in the management of this particular type of pneumothorax.
Clinical Summary
An asymptomatic 52-year-old woman was referred to our attention
for the detection on a chest radiogram of a total collapse of the right
lung. After chest drain insertion, a computed tomographic scan
showed a 5-cm right upper lesion with no obvious mediastinal nodal
enlargement. The surgical approach entailed a right video-assisted
thoracoscopy to rule out pleural dissemination; a subpleural tear
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During the same session, a right upper lobectomywith complete me-
diastinal nodal dissection was performed via a right totally muscle-
sparing hybrid (video-assisted/open) approach. The final pathologic
report showed a pT2 N0 adenocarcinoma.
Both non–small cell and small–cell lung cancers have been asso-
ciated with pneumothorax either as a presenting sign or as a treat-
ment-related complication. When primary lung cancer manifests
itself in young patients with a spontaneous pneumothorax, the prog-
nostic outlook is considered acceptable because an early diagnosis
often leads to early treatment.2 Conversely, if the pneumothorax
appears late in the course of the disease, it generally portends an
ominous prognosis.3,4
Extrathoracic malignant tumors can equally metastasize to the
lung and virtually all histotypes have been associated with the onset
of a pneumothorax. The etiopathogenesis of the pneumothorax can
be multifactorial,1,2 and the same side as the cancer or the contralat-
eral side can be affected depending on whether the actual tumor is
the direct cause of the pneumothorax.
The treatment of this condition depends on the patient’s age and
performance status, cardiorespiratory functional reserve, and life
expectancy. The ideal situation is to radically treat the cancer by
a formal resection or by lung volume reduction surgery as per recent
reports.3-5 However, when this is not feasible, alternative manage-
ment aimed primarily at achieving pleurodesis3 should be consid-
ered after an adequate, but not prolonged, observation period
(up to 2 weeks).
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imited information exists on the incidence of symptom-
atic venous thromboembolism (VTE) in patients under-
going chest surgery for lung cancer. Several factors
increase the thromboembolic risk in patients undergoing
surgery for lung cancer: the intrinsic procoagulant effect of cancer,
extensive surgical intervention, dependent limb position in the oper-
ating room, and vessel injury consequent to the operation. Further-
more, these patients might be especially vulnerable to pulmonary
embolism (PE) because of the loss of lung tissue and the presence
of chronic obstructive pulmonary disease and cardiovascular dis-
eases caused by smoking.1
Older studies found a very high incidence of thromboembolic
events in these patients.2,3
However, the risk of thromboembolic complications in lung can-
cer surgery might have changed over the last years. Extensive use of
antithrombotic prophylaxis, improvement in surgical techniques
and perioperative care, and more prompt mobilization might have
reduced the risk of VTE.
Therefore, the aim of our study was to provide up-to-date reliable
data on the incidence of venous thromboembolic complication in
a large cohort of patients undergoing chest surgery for malignant
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lung disease. Furthermore, the raw mortality rate and the mortality
rate related to PE were evaluated.
Clinical Summary
We performed a chart review of all patients undergoing chest sur-
gery for malignant lung disease who were operated on between Jan-
uary 1, 2002, and December 1, 2004, at St Joseph’s Hospital,
Hamilton, Ontario, Canada, and between January 1, 2005, and
December 1, 2006, at 2 university hospitals in Italy (Varese and
Palermo). The charts of eligible patients were reviewed for baseline
clinical characteristics, including sex, age, prior history of cardio-
vascular disease, and use and type of antithrombotic prophylaxis.
Perioperative mortality and all objectively confirmed venous throm-
boembolic events were noted. Notes of follow-up ambulatory surgi-
cal visits were also reviewed within 4 weeks of hospital discharge
after surgical intervention to ensure that cases of VTE occurring
after discharge were not missed. The study protocol was approved
by the regional institutional review boards.
Baseline characteristics are summarized in Table 1. Six hundred
ninety-three patients were identified (mean age, 66.7 years; range,
23–90 years); 418 (60.6%) patients were male, and the median
length of hospitalization was 7 days. One hundred fifty-five
(22.5%) patients had a history of cardiovascular disease. Almost
90% of patients attended at least 1 follow-up ambulatory surgical
visit after discharge. Postoperative antithrombotic prophylaxis
with unfractionated heparin at a dose of 5000 U twice daily was
used in 464 (67.2%) patients, and low-molecular-weight heparin
was used in 153 (22.2%) patients. Only 16 (2.3%) patients did not
receive antithrombotic prophylaxis. Five hundred seven (73.5%) pa-
tients had primary lung cancer, and 183 had secondary malignant
lung cancer. Lung primary adenocarcinoma, epidermoid carcinoma,
and anaplastic cancer were the most common cancer histologies.
Ninety-three (13.5%) patients underwent pneumectomy, and 597
(86.5%) underwent lobectomy or wedge resection.
There were 12 (1.7%) venous thromboembolic complications, of
which 9 (1.3%) were PEs. All these complications occurred while
patients were receiving antithrombotic prophylaxis with unfractio-
nated or low-molecular-weight heparin. Twenty-one (3.0%) patients
died during hospitalization. However, mortality could be attributed
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